Navigation Links
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Date:8/19/2007

Multi-Center International Study to Determine the Efficacy of LBH589 in

Patients with Relapsed or Refractory Multiple Myeloma

NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) today announced its participation in a Phase II study to determine the efficacy of LBH589 for the treatment of patients with relapsed or refractory multiple myeloma. LBH589 is an orally administered deacetylase inhibitor developed by Novartis Pharmaceuticals.

The MMRC is the only research model of its kind bringing together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell. In addition to its most recent partnership with Novartis, the MMRC is facilitating several other clinical trials, including a Phase I study of NPI- 0052, a proteasome inhibitor, in collaboration with Nereus Pharmaceuticals, and a Phase I study of perifosine, lenalidomide (REVLIMID(R)), and dexamethasone in collaboration with Keryx Biopharmaceuticals.

"Deacetylase inhibitors may represent a new treatment options for cancer patients and the MMRC is proud to work with Novartis to advance this important clinical program," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, as well as a myeloma patient. "This trial and the others the MMRC is facilitating demonstrate the importance of novel collaborations in bringing new treatments to patients."

Named ALPHA-MM, this trial is a single arm, open label, multi-center global study that will enroll 144 patients in the United States, Canada, and Europe. MMRC Member Institutions that will enroll patients are Dana-Farber Cancer Institute, City of Hope National Medical Center, Emory University, Hackensack University Medical Center, Mayo Clinic, H. Lee Moffitt Cancer Center & Research Institute, and Washington University.

This trial is open to patients with relapsed or r
'/>"/>

SOURCE The Multiple Myeloma Research Consortium

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...., May 16 /- Veridex, LLC announced t...orporation of America Holdings,(LabCorp), has comm...prostate cancer. The new assay uses the biological...er, detecting the methylation of the gene,GST-Pi. ...rimarily in,cancer. Veridex is developing the meth...
(Date:5/15/2008)... Confirm Efficacy for Population Most Affected by ...y 16 /-,Bayer HealthCare Ph...,(Nasdaq: ONXX ) today announced that Nexavar(R) ... survival by 47.3 percent (HR=0.68;,p-value=0.014)...ced,hepatocellular carcinoma (HCC), or primary liv...
(Date:5/15/2008)...O, May 15 /- Medivation, In... an ongoing Phase 1-2 clinical,trial of its novel ...sented,in an oral presentation at the 44th America...ng in Chicago., Session title: New Targeted Str... date and time: Monday, June 2 at 11:30 a.m. Centr...
(Date:5/15/2008)...Presented at ASCO Showed Acceptable Tolerability P...and 4 Neuropathy, WOODCLIFF LAKE, N.J., May 15 /P... agent eribulin mesylate (E7389) demonstrated acti...ith locally advanced or metastatic,breast cancer, ...inical,trial. The study also suggests that eribuli...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Media highlights in the March 1 issue of Biophysical Journal 2310 1Sunrise Announces Release Date for Fourth Quarter Preliminary Selected Financial and Operating Data 12666 1Doing Angioplasty Long After Heart Attack Still Worth It Analysis Shows 12661 1Doing Angioplasty Long After Heart Attack Still Worth It Analysis Shows 12661 2Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call 12656 1
(Date:5/16/2008)... Live Web Cast Scheduled for May 19 at 10:15 a.m....tCall/ - Response Biomedical,Corporation (TSX: RBM...,Chief Executive Officer, is scheduled to present ...re Conference on Monday May 19th at 10:15 a.m.,EDT...ailable on the Company,s,Web site at, http://www.r...
(Date:5/16/2008)...t this country needs is more unemployed politician...swire-FirstCall/ -- Although nearly all,voters pla... issues" list,a looming federal budgetary crunch ...y of the current presidential candidates is likely...te Majority Leader Bill Frist., Jousting with Pri...
(Date:5/16/2008)...ONDON, May 16 /PRNewswire/ -- Huntsworth plc (LSE:... relations and healthcare communications,group hea...ent report with,respect to the Group,s performance...h 31, 2008)., The statement follows below., 15... plc, Interim Management Sta...
(Date:5/16/2008)... Appeals for Funds Focus on Millions of Children S...The U.S. Fund for UNICEF and The,Advertising Counc... promote,a series of national public service annou...uding Ben Stiller, Nicole Ritchie, Joel Madden, Da...ed to help survivors of the,Myanmar cyclone. The A...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3
..., Feinberg School of Medicine have reported in Jou... inactivity and obesity // reduces the cardio-resp...sterol and blood pressure levels leading to increa...ers conducted their survey in U.S. population in t...
...reating psychological disorders. Carl Rogers intro...as been lot of questions about this technique. But... view problems of their patients from a different ...ory to various existing approaches present at that...
.... Zhou, 41 year old factor worker from the Sanming...he seventh victim of bird flu infection in China, ...er and pneumonia. It is not yet known how she got... contact with poultry and moreover she did not tak...
... by rabies which is transmitted through the saliva...ion // is required for a person who is bitten by .... If bite from an animal is unprovoked, it is safe...tested for the infection. If found infected, the a...
Other Medicine News:
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Medicine Products: